News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gemin X Biotechnologies Inc. Initiates Phase 1/2 Combination Trials With GX15-070 In Non-Small Cell Lung Cancer And Mantle Cell Lymphoma



1/31/2007 12:03:04 PM

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Gemin X announced today the initiation of a Phase 1/2 clinical trial of GX15-070 in combination with docetaxel (Taxotere®), a chemotherapeutic agent, in patients with non-small cell lung cancer (NSCLC), and a Phase 1 trial in combination with bortezomib (Velcade®), a proteosome inhibitor, in patients with mantle cell lymphoma (MCL). GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES